The PARP inhibitor ABT-888 synergizes irinotecan treatment of colon cancer cell lines
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The PARP inhibitor ABT-888 synergizes irinotecan treatment of colon cancer cell lines
Authors
Keywords
PARP, PARP inhibitor, VE-821, Irinotecan, SN38, Colon cancer
Journal
INVESTIGATIONAL NEW DRUGS
Volume 31, Issue 2, Pages 461-468
Publisher
Springer Nature
Online
2012-10-08
DOI
10.1007/s10637-012-9886-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Advances in using PARP inhibitors to treat cancer
- (2012) Shivaani Kummar et al. BMC Medicine
- PARPs and the DNA damage response
- (2012) F. G. Sousa et al. CARCINOGENESIS
- Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53
- (2012) Chris T. Williamson et al. EMBO Molecular Medicine
- Camptothecin induces p53-dependent and -independent apoptogenic signaling in melanoma cells
- (2011) E. Rudolf et al. APOPTOSIS
- Poly(ADP-ribose) polymerase-1 (PARP-1) pharmacogenetics, activity and expression analysis in cancer patients and healthy volunteers
- (2011) Tomasz Zaremba et al. BIOCHEMICAL JOURNAL
- Synthetic lethality: exploiting the addiction of cancer to DNA repair
- (2011) M. Shaheen et al. BLOOD
- The role of PARP in DNA repair and its therapeutic exploitation
- (2011) M Javle et al. BRITISH JOURNAL OF CANCER
- Poly(ADP-ribose) polymerase inhibition enhances p53-dependent and -independent DNA damage responses induced by DNA damaging agent
- (2011) Diana Nguyen et al. CELL CYCLE
- The Poly(ADP-ribose) polymerases (PARPs): New roles in intracellular transport
- (2011) Zakaria Y. Abd Elmageed et al. CELLULAR SIGNALLING
- Irinotecan and DNA-PKcs inhibitors synergize in killing of colon cancer cells
- (2011) David Davidson et al. INVESTIGATIONAL NEW DRUGS
- Effects of the novel DNA dependent protein kinase inhibitor, IC486241, on the DNA damage response to doxorubicin and cisplatin in breast cancer cells
- (2011) David Davidson et al. INVESTIGATIONAL NEW DRUGS
- Enhanced Killing of Cancer Cells by Poly(ADP-ribose) Polymerase Inhibitors and Topoisomerase I Inhibitors Reflects Poisoning of Both Enzymes
- (2011) Anand G. Patel et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings
- (2011) Thomas Helleday Molecular Oncology
- Optimal Delivery of Cytotoxic Chemotherapy for Colon Cancer
- (2010) Laura Raftery et al. CANCER JOURNAL
- Alkylation DNA damage in combination with PARP inhibition results in formation of S-phase-dependent double-strand breaks
- (2010) Michelle L. Heacock et al. DNA REPAIR
- Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses inBRCACarrier Ovarian Cancer Correlating With Platinum-Free Interval
- (2010) Peter C. Fong et al. JOURNAL OF CLINICAL ONCOLOGY
- Therapeutic Potential of Poly(ADP-ribose) Polymerase Inhibitor AG014699 in Human Cancers With Mutated or Methylated BRCA1 or BRCA2
- (2010) Yvette Drew et al. JNCI-Journal of the National Cancer Institute
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
- (2010) Andrew Tutt et al. LANCET
- A Phase IB Trial of Intravenous INO-1001 Plus Oral Temozolomide in Subjects with Unresectable Stage-III or IV Melanoma
- (2009) Agop Y. Bedikian et al. CANCER INVESTIGATION
- ATM- and ATR-mediated response to DNA damage induced by a novel camptothecin, ST1968
- (2009) Valentina Zuco et al. CANCER LETTERS
- Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies
- (2009) Shivaani Kummar et al. JOURNAL OF CLINICAL ONCOLOGY
- Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity
- (2009) T. M. Horton et al. MOLECULAR CANCER THERAPEUTICS
- Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers
- (2009) Peter C. Fong et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors
- (2008) R. Plummer et al. CLINICAL CANCER RESEARCH
- Interaction between PARP-1 and ATR in mouse fibroblasts is blocked by PARP inhibition
- (2008) Padmini S. Kedar et al. DNA REPAIR
- Resistance to therapy caused by intragenic deletion in BRCA2
- (2008) Stacey L. Edwards et al. NATURE
- High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
- (2008) S. Rottenberg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now